Foscarbidopa is a medication which acts as a prodrug for carbidopa. It is used in a subcutaneous infusion as a fixed-dose combination with foslevodopa for the treatment of Parkinson's disease, under the brand name Vyalev.[1][2]

Foscarbidopa
Identifiers
  • (2S)-2-hydrazinyl-3-(3-hydroxy-4-phosphonooxyphenyl)-2-methylpropanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC10H15N2O7P
Molar mass306.211 g·mol−1
3D model (JSmol)
  • C[C@](CC1=CC(=C(C=C1)OP(=O)(O)O)O)(C(=O)O)NN
  • InChI=1S/C10H15N2O7P/c1-10(12-11,9(14)15)5-6-2-3-8(7(13)4-6)19-20(16,17)18/h2-4,12-13H,5,11H2,1H3,(H,14,15)(H2,16,17,18)/t10-/m0/s1
  • Key:PQUZXFMHVSMUNG-JTQLQIEISA-N

References

edit
  1. ^ Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR (August 2024). "Subcutaneous Levodopa: A New Engine for the Vintage Molecule". Neurology and Therapy. 13 (4): 1055–1068. doi:10.1007/s40120-024-00635-4. PMC 11263521. PMID 38874708.
  2. ^ Fung VS, Aldred J, Arroyo MP, Bergquist F, Boon AJ, Bouchard M, et al. (2024). "Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance". Clinical Parkinsonism & Related Disorders. 10: 100239. doi:10.1016/j.prdoa.2024.100239. PMC 10900117. PMID 38419617.